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Photodynamic therapy (PDT) involves the action of photons on photosensitive molecules, where atomic oxygen or
OH− molecular species are locally released on pathogenic human cells, which are mainly carcinogenic, thus causing
cell necrosis. The efficacy of PDT depends on the local nanothermodynamic conditions near the cell/nanodrug
system that control both the level of intracellular translocation of nanoparticles in the pathogenic cell and their
agglomeration on the cell membrane. Dendrimers are considered one of the most effective and promising drug
carriers because of their relatively low toxicity and negligible activation of complementary reactions. Polyamidoamine
(PAMAM) dendrite delivery of PDT agents has been investigated in the last few years for tumour selectivity, retention,
pharmacokinetics and water solubility. Nevertheless, their use as drug carriers of photosensitizing molecules in PDT
for cardiovascular disease, targeting the selective necrosis of macrophage cells responsible for atheromatous plaque
growth, has never been investigated. Furthermore, the level of aggregation, translocation and nanodrug delivery
efficacy of PAMAM dendrimers or PAMAM/zinc phthalocyanine (ZnPc) conjugates on human atheromatous tissue
and endothelial cells is still unknown.
In this work, the aggregation of PAMAM zero generation dendrimers (G0) acting as drug delivery carriers, as well
as conjugated G0 PAMAM dendrimers with a ZnPc photosensitizer, to symptomatic and asymptomatic human
carotid tissues was investigated by using atomic force microscopy (AFM). For the evaluation of the texture
characteristics of the AFM images, statistical surface morphological and fractal analytical methodologies and
Minkowski functionals were used. All statistical quantities showed that the deposition of nanodrug carriers on
healthy tissue has an inverse impact when comparing to the deposition on atheromatous tissue with different
aggregation features between G0 and G0/ZnPc nanoparticles and with considerably larger G0/ZnPc aggregations
on the atheromatous plaque. The results highlight the importance of using PAMAM dendrimer carriers as a novel
and promising PDT platform for atherosclerosis therapies.
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Figure 1 Simplified schematic lay-out of PDT in atherosclerosis. The
lipid core plaque (LC) is responsible for stenosis of the aorta (AO).
Photons (hv) guided by a fibber (F) illuminate the microphage cells
in the plaque (LLM), inducing necrosis following nanoparticle (NP)
uptake. SI, side illumination of atheromatous plaque; I, intima; SMC,
smooth muscle cells; M, media; A, adventida; FC, foam cell; BF, blood
flow; EC, endothelial cells; LDL, low-density lipoprotein; HDL,
high-density lipoprotein.
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Atherosclerosis is a common source of many cardiovas-
cular diseases that cause stroke and heart attack. Athero-
sclerosis inflammation starts in the intima and media
layers of the arterial wall section by forming a plaque,
eventually leading to an abrupt rupture of the arterial
wall. Although many pharmaceutical agents are available
to treat different manifestations of atherosclerosis, their
systemic delivery has serious disadvantages, including
considerable side effects and low efficacy at tolerated doses
[1]. Recent advances in nanotechnology have provided new
tools for the efficient diagnosis and therapy of atheroscler-
osis [2-7]. Photodynamic therapy (PDT), which uses func-
tionalized nanoparticles (NPs) that are selectively attached
to the diseased tissues or cells, is a promising method for
the localized treatment of atherosclerosis [8].
The action of PDT consists of the selective attachment
of photosensitizing molecules (PSs) to the diseased tis-
sue. Irradiation of tissues at specific wavelengths of light
activates the PSs, thus promoting cell death [9]. Once
irradiated, a PS molecule is transferred into an excited
molecular electronic state by the absorption of one pho-
ton and eventually transfers its energy to its surrounding
molecular oxygen, generating reactive oxygen species
(ROS), either singlet oxygen or OH− molecules [10,11].
Due to its short life-time, ROS diffuse within the tissue
at a distance of up to few tenths of a nanometer; there-
fore, the biological damage is limited to the sub cellular
location of the action of PSs [12].
The rationale for using PDT in atherosclerosis is justi-
fied by a few experimental results [13], where different
PSs, such as porphyrins and phthalocyanines (Pcs), are
shown to selectively accumulate in the atherosclerotic
plaque rather than in the adjacent normal vessel wall (e.g.
endothelium), as seen in Figure 1. The overall aim of PDTs
is to stop the biological activities of macrophage cells in
atheromatous plaques by necrosis, as described previously
in the work of McCarthy et al. [14-17] (Figure 1).
Furthermore, various PS phthalocyanine molecules have
advantageous photophysical properties [18], owing to the
selectivity of light absorption at 670 nm, where the depth of
photon penetration in tissues is twice as high as the pene-
tration depth of porfimer sodium (Photofrin) at 630 nm
[19]. In PDTs, the singlet oxygen’s quantum yield is high
enough [20] to account for a considerable cell necrosis.
Despite the fact that most of the PSs used in PDTs
have low biocompatibility and water-solubility, which
limit their effective clinical usage [21,22], both issues
are addressed via conjugation of PSs with proper nanocar-
rier materials [23-25]. The main advantages of using
polymer-PS nanodrug conjugates are the high water solu-
bility of the hydrophobic drugs, controlled drug release
under certain conditions (e.g. pH or presence of enzymes),
resistivity of drugs against degradation, prolonged plasmalife-time, improved biocompatibility, altered biodistribution
and either specific accumulation in localized sites or en-
hanced permeability and retention (EPR) in cells [26]. How-
ever, in any conjugated system, strong aggregation or self-
association of the PSs occurs, leading to detrimental ef-
fects, such as low drug delivery efficacy or even tissue
damage [27,28].
In the special case of zinc phthalocyanine (ZnPc), suc-
cessful conjugation with different nanocarriers has already
been demonstrated in many other studies [25,29-36], and
dendritic delivery of PDT agents has been investigated
within the last few years to improve upon tumour selectiv-
ity, retention and pharmacokinetics [37,38].
Because of their unique synthetic roots, dendrimers
combine a defined composition and monodispersity with
a high molecular mass, giving them interesting physical
and chemical properties [39]. A large number of func-
tional end-groups are responsible for high solubility and
reactivity. Internal cavitations at the nano/microscale can
be utilized in transporting small molecules as well [40-42].
Polyamidoamine (PAMAM) molecules comprise a novel
class of spherical, biocompatible, safe, non-immunogenic
and highly branched or cascade polymers [42] studied as
model nanoparticles in biomedical applications, including
drug delivery [43-45], owing to their relative large nano-
metric size and water solubility [46]. Moreover, PAMAM
dendrimers can induce multivalence effects, similar to the
polyvalent interactions in biological systems [47], but any
successful PDT methodology in atherosclerosis must avoid
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addition, the efficacy of penetration into the endothelial
cells, as well as the selectivity, aggregation and translocation
of PAMAM dendrimers or PAMAM/ZnPc conjugates, on
human atheromatous tissue is unknown. Recently, it was
established that the efficiency of intracellular nanodrug up-
take in a cell and the level of agglomeration on the cell
membrane are functions of the local nanothermodynamic
conditions near the cell-wall/nanodrug system [28].
In this work, the adhesion and aggregation characteris-
tics of different zero generation PAMAM dendrimers (G0)
acting as drug delivery carriers, as well as conjugated G0
PAMAM dendrimers with a ZnPc photosensitizer (G0/
ZnPc), to symptomatic (atheromatous) and asymptomatic
(healthy) human carotid tissues were studied by using
atomic force microscopy (AFM), statistical surface analysis
and different fractal analytical methodologies. For the
evaluation of the texture characteristics of the AFM im-
ages and the adhesion and aggregation characteristics of
the nanodrugs, scaling from 1 × 1 μm to 5 × 5 μm, fractal
analytical methodologies (variance, power spectrum, cube
counting and triangulation) and Minkowski functionals
(volume, boundary, connectivity) were used, together with
statistical surface analysis, allowing for differentiation in
the selective aggregation of nanodrugs in symptomatic
and asymptomatic carotid tissues.
Methods
G0 PAMAM dendrimers
A G0 PAMAM dendrimer (1,4-diaminobutane core,
carbomethoxy pyrolidinone terminated, GEN 0.0, C48
H76N10O16) (NanoSynthons, LLC, Mt Pleasant, Michigan,
USA) in lyophilized form was used. A quantity of 60 mg
was resolved in 1 ml of distilled water, resulting in a con-
centration of 0.05 M. Then, the solution was further di-
luted to a final concentration of 0.025 M.
Tissues
Carotid tissues were kindly offered by Poznan University
of Medical Sciences, Poland. They were surgically re-
moved from patients who had atheromatous plaques
near the common carotid artery and also from patients
who had an atheromatous plaque in other areas of the
artery; the major carotid artery branch was asymptom-
atic. Tissues stained in paraformaldehyde were shipped
and preserved in 70% ethanol. They were hydrated with
Ringer’s solution with the osmotic pressure as blood
(mixture of NaCl, KCl, CaCl2 and NaHCO3), and then a
microsection of 60 μm was acquired both in the asymp-
tomatic and symptomatic area of the carotid. The micro-
section was placed on a silica wafer or glass and was
poured for 30 min with the aquatic solution of G0
dendrimers or conjugated molecules of ZnPc and G0
dendrimers. Samples were treated according to the ethicissues specified in the FP7-NMP-2012-LARGE-6 ‘Cos-
moPhos-Nano’ project (reference number: 310337). The
study was approved by the ethics committee of Poznan
University of Medical Sciences, Poland.
Photonic conjugation of G0 dendrimer and ZnPc
Zinc phthalocyanine (Sigma-Aldrich, St. Louis, MO,
USA) was used as the active part of the nanodrug. Pho-
tonic conjugation of the dendrimer and ZnPc was
achieved with laser light at 157 nm (LPF 200, Lambda-
Physik (since 2006), Coherent, Santa Clara, CA, USA)
[48,49] to avoid the use of additional catalysts that might
enhance agglomeration; ZnPc/G0 dendrimer solutions
were prepared by diluting 4 × 10−5 kg of lyophilized G0
in 10−3 l H2O in a final concentration of 0.038 M. Subse-
quently, ZnPc (MW = 577.91 × 10−3 kg) was partially di-
luted in 5 × 10−3 l phosphate-buffered saline (PBS) in a
final concentration of 0.034 M. The PBS buffer was se-
lected for its biocompatibility to avoid toxicity. Two
parts of the G0 solution were mixed with one part ZnPc.
To avoid the creation and consequent precipitation of
aggregated G0 and ZnPc, the solution was sonicated for
30 min. A total of 1.5 × 10−3 l of the final solution was
placed into a cell that had CaF2 windows, which are
transparent at VUV wavelengths. The cell was installed
in front of the 157-nm (7.8 eV) laser. The energy, flu-
ence, pulse duration at full width at half maximum and
the repetition rate of the unfocused laser beam per laser
pulse were 24 mJ, 75 Jm−2, 15 ns and 15 Hz, respect-
ively. At 157 nm, there is a complete bond breaking of
all the organic molecules [50]. The parent molecule dis-
integrates into small fragments that are atomic, diatomic
or triatomic. This is because the dissociative excited
states of the small radicals occupy the energy range
above 6.5 eV (200 nm). This unique functionality at low
wavelengths and 157 nm allows for the unique bio-
functionalities of surfaces [51,52]. Following laser irradi-
ation at 157 nm, a drop of the liquid was deposited on a
Si wafer and left to dry. Then, the film was studied by μ-
Raman spectroscopy (100 to 3,200 cm−1, 850-nm diode
laser). The μ-Raman spectra of G0 and ZnPc powder are
also included in Figure 2 for comparison. The new bands
at approximately 1,923 cm−1 and 2,298 cm−1 were attrib-
uted to photoconjugated G0/ZnPc as a result of the for-
mation of new bonds following the dissociation of the
parent molecules.
Atomic force microscopy
Images of symptomatic and asymptomatic carotids, as
well as symptomatic and asymptomatic carotids with the
addition of the G0 and G0/ZnPc conjugates were ac-
quired under ambient conditions by using an AFM
(d’Innova, Bruker, Madison, WI, USA). AFM provides
high-resolution imaging and measurements of surface
Figure 2 μ-Raman spectra (100 to 3,200 cm−1, 850-nm diode laser)
G0 and ZnPc solution. The Raman spectra of G0 and ZnPc powder
are also shown for comparison. The new bands around 1,923 cm−1
and 2,298 cm−1 can be attributed to the photo-conjugated G0/ZnPc.
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images of symptomatic/asymptomatic carotids were ac-
quired in tapping-mode using a phosphorus-(n)-doped
silicon cantilever (RTESPA, Bruker, Madison, WI, USA)
with a nominal spring constant of 40 N/m at approxi-
mately 300 kHz resonance frequency and a nominal
radius of 8 nm (Figure 3). The AFM images were ob-
tained at different scanning areas at a maximum scan-
ning rate of 0.5 Hz with an image resolution of 512 ×
512 pixels. Imaging was carried out at different scales
from 1 to 5 μm to verify the consistency and robustness
of the evaluated structures. The AFM data were proc-
essed with WSXM™ free software [53].Surface roughness parameters
The root mean square surface roughness (Rq), the sur-
face roughness (Ra), the mean Zð Þ; media (Z1/2), modeFigure 3 3D-AFM image of atheromatous plaque. (a) 100 × 100 μm size im(Zmp) and range (Rt) heights, the maximum valley depth
(Rmvd), the maximum peak height (Rmph), skewness (Rsk)
and kurtosis (Rku) are used to quantify surface rough-
ness. The statistical parameters of surfaces are shown in
Additional file 1 and partially in Table 1. They are calcu-








Zi−Zj j; Z ¼ 1N
X
Zij j. The Z1/2 and Zmp parameters
are calculated from the probability distribution function
(PDF) of heights f(Z) that satisfy the equations
R Z1=2
−∞ f Zð Þ
dZ ¼ R∞Z1=2 f Zð ÞdZ ¼ 1=2 and ddZ
R∞
−∞ f Zð ÞdZ ¼ 0. Additionally, Rt = |Zmax − Zmin|, Rmvd ¼ Zi−Zð Þmin ;
Rmph ¼ Zi−Zð Þmax ; Rsk ¼ 1NR3q
XN
i¼0
Zi−Zj j3; Rku ¼ 1NR4q
XN
i¼0
Zi−Zj j4 , where Zi is the ith height and N is the number
of data points over which Zi is collected.
Recently, the surface roughness of arteries acquired
from ultrasound images was used for the early diagnosis
of atherosclerosis [54]. However, it can only be used for
qualitative investigations because they differ by the scale
of measurement. It also does not include information
about the spatial distribution of the topography.
Fractal methods
The use of fractal geometry, with concepts such as self-
similarity and self-affinity, introduced by Mandelbrot
[55], has changed and broadened the characterization of
surfaces as well as many phenomena and processes.
Today, several algorithms have been developed in the lit-
erature for the estimation of fractal dimensions from the
AFM images. The fractal dimension Df is a measure of
the degree of variation of a surface from its topological
ideal and is related to both surface roughness and its
topological entropy. It describes the degree of chaoticity
of a surface and is a number lying between 2 for a smooth
surface and 3 for an extremely rough surface [56].age. (b) 20.5 × 20.5 μm size image, higher magnification of Figure 3a.
Table 1 Surface characteristics obtained from AFM
images
Z(nm) Ra(nm) Rq(nm)
1 × 1 μm
Healthy 24.91 7.78 9.96
Atheromatous 49.37 7.87 10.12
Healthy + PAMAM 8.74 1.62 2.18
Glass + PAMAM (0.05 M) 3.54 0.53 0.79
Glass + PAMAM (0.025 M) 1.89 0.20 0.38
2 × 2 μm
Healthy 78.92 15.77 20.12
Atheromatous 56.46 12.90 16.41
Healthy + PAMAM 41.49 3.65 5.48
Atheromatous + PAMAM 166.63 17.23 24.09
Atheromatous + PAMAM + ZnPc 175.17 32.37 41.97
3 × 3 μm
Atheromatous 102.26 16.96 21.22
Atheromatous + PAMAM + ZnPc 280.84 46.62 60.30
5 × 5 μm
Healthy 133.98 34.58 43.20
Atheromatous 166.30 30.81 39.06
Atheromatous + PAMAM 266.32 50.96 65.86
Atheromatous + PAMAM + ZnPc 260.82 69.35 87.03
Glass + PAMAM (0.025 M) 19.23 2.98 6.57
AFM, atomic force microscopy; PAMAM, polyamidoamine; ZnPc,
zinc phthalocyanine.
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characterization of biological surfaces or structures using
magnetic resonance imaging [57-59], ultrasound [60,61]
or other techniques [62,63]. However, evaluations of frac-
tal parameters from AFM images for biological surfaces
are scarce [64,65]. For example, Bitler et al. [64] evaluated
the fractal dimension of the macrophage cell membrane
and tested the sensitivity of the fractal dimension value to
submicron changes in membrane morphology using high-
resolution AFM imaging.
In this work, the fractal dimension Df was calculated
from the AFM data using B-Spline interpolation with
four methods, i.e. cube counting, triangulation, variance
and power spectrum distribution, using the free and
open source software program Gwyddion [66]. For the
four methods, all of the slopes were determined using a
linear fit. Before fractal analysis, all AFM images were
processed using a dilation algorithm to compensate for
the convolution between the tip and the surface and tip
distortions caused by the orientation of the tip and the
forces between the tip and surface [67]. For dilation, a
contact tip with a pyramid shape and a tip apex of 12
nm that was rotated by 45° was used as the model tipfor all surface scan reconstructions [68]. For fractal dimen-
sion estimation based on structure function and variation
methods, we developed custom MATLAB (MathWorks
Inc., Natick, MA, USA) codes. The original images were
opened, and processed, and the fractal dimension was
evaluated with these programs.
Minkowski functionals
The Minkowski functionals were used to describe the
global geometric characteristics of structures. Two-
dimensional discrete variants of volume V, surface S
and connectivity (Euler-Poincaré Characteristic) x were
calculated using the Gwyddion™ software [66]. The
Minkowski functionals provide parameters that allow
for the fundamental quantification of the dispersion.
They represent a method to describe the amount of
connectivity by analysing the relationship of connected
pixels and unconnected pixels present in an image.
Minkowski functionals are very effective at describing
complex morphologies observed in images [69-71].
Results
AFM morphology, RMS and height distribution
It is found from Table 1, Figures 4, 5, 6 and 7 and
Additional file 1 that the PDF of heights f(Z) is unimodal,
because the statistical mean, media and mode values of
height are almost the same. Plain 1 × 1 μm AFM images of
a carotid tissue, either healthy (H), Figure 4a, or atheroma-
tous (A), Figure 4b, display higher Z and Rq values than
healthy carotid samples with G0 dendrimers (G0-H)
(Figure 4c and Table 1). The corresponding Z values
are approximately 8.74 nm (G0-H) versus approxi-
mately 24.91 nm (H) or approximately 49.37 nm (A).
The Rq values are approximately 2.18 nm (G0-H) versus
approximately 9.96 nm (H) or approximately 10.12 nm (A).
Deposition of the G0 dendrimer on a glass substrate,
Figure 4d,e, indicates even lower roughness values, Z
~3.54 nm and Rq~0.79 nm and Z ~1.89 nm and Rq~0.38
nm for 0.05 and 0.025 M G0 concentrations, respectively.
The cluster size distribution shifts to the right at higher
concentrations (Figure 4f).
A similar trend of surface roughness values appears for
the 2 × 2 μm AFM images (Figure 5a,b,c). For the G0 den-
drimers on healthy and atheromatous tissues, Z ~41.49
nm (G0-H) and Rq~24.09 nm (G0-H) versus Z ~78.92 nm
(H) and Rq~20.12 nm (H). In contrast, the deposition of
G0 dendrimers on atheromatous carotid tissues, Figure 5d,
results in higher surface roughness values, Z ~166.63 nm
(G0-A) and Rq~24.09 nm (G0-A), compared to the values
of Z ~56.46 nm (A) and Rq~16.41 nm (A).
The addition of the conjugated G0/ZnPc drug on the
atheromatous carotid tissue, Figure 5e, has a similar im-
pact on the surface roughness parameters as the addition
Figure 4 AFM images (1 × 1 μm) showing (a) a healthy carotid tissue, (b) an atheromatous carotid tissue, (c) a healthy carotid tissue with G0
PAMAM dendrimers, (d) a solution (0.05 M) of dendrimers on glass and (e) a highly diluted solution (0.025 M) of dendrimers on glass. (f) Height
distribution of the (a)-(e) samples.
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the Rq value is much higher, Rq~41.49 nm. This tendency is
strengthened by the results obtained from the 3 × 3 μm
AFM images, where the Z and the Rq surface roughness
values for the plain atheromatous carotid tissue, Figure 6a,
are Z ~102.26 nm (A) and Rq~21.2 nm (A). These surface
roughness values are lower than those of the atheromatoustissue with the addition of the conjugated G0/ZnPc solu-
tions, Figure 6b, where Z ~280.84 nm (G0/ZnPc) and
Rq~60.30 nm (G0/ZnPc). Finally, the 5 × 5 μm AFM im-
ages, Figure 7, also demonstrated that the addition of the
G0 dendrimers, Figure 7c, or G0/ZnPc, Figure 7d, on the
atheromatous tissue affects the surface roughness values
significantly, indicating a higher level of agglomeration. On
Figure 5 AFM images (2 × 2 μm) showing (a) a healthy carotid tissue, (b) an atheromatous carotid tissue, (c) a healthy carotid tissue with G0 PAMAM
dendrimers, (d) an atheromatous carotid tissue with G0 PAMAM dedrimers and (e) an atheromatous carotid tissue with dedrimers conjugated with
ZnPc. (f) The corresponding height distribution of the 2 × 2 μm samples.
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the healthy tissue indicate a low level of agglomeration with
average surface parameters that are smaller or equal to those
of the healthy tissues. Overall, the results point out that the
type of biosurface mediates the agglomeration efficiency of
nanodrugs, in agreement with previous results [28].
Size statistics of aggregation of ZnPc nanoparticles on
gold (Au) and Si standard test surfaces is different than
the aggregation of G0 on the same surfaces. ZnPcnanoparticles tend to aggregate at average sizes larger
than the surface roughness parameters of the test sur-
faces (Additional file 2). This response is owing to the
presence of electron charges on the surface of ZnPc
nanoparticles and demonstrated by conductive atomic
force microscopy (Additional file 2). In case of conjuga-
tion of ZnPc with the G0 dendrimers, the negative
charges are compensated to give nearly neutral nanopar-
ticles of smaller size.
Figure 6 AFM images (3 × 3 μm) showing (a) an atheromatous
carotid tissue, (b) an atheromatous carotid tissue with G0 PAMAM
dedrimers conjugated with ZnPc. (c) The corresponding height
distribution of the 3 × 3 μm samples.
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In Figures 8, 9, 10 and 11, the log-log plots used for the
calculation of fractal dimensions by applying different
methodologies for the 1 × 1 μm, 2 × 2 μm, 3 × 3 μm
and 5 × 5 μm sets of AFM images are illustrated. The
evaluated fractal dimensions from the four different
methods are presented in Table 2. In general, the three
methods, namely, variance, cube counting and triangula-
tion, give fractal dimensions that have a similar trend in
most cases. In contrast, the power spectrum results notonly differ from the other methods but also, most im-
portantly, have values below 2; hence, this method is
inappropriate to characterize the samples. It is most im-
portant that despite a difference in the absolute values
calculated by the three different approaches, the effect of
the deposition of G0 dendrimers is consistent. On all
scales, a comparison between the images of healthy and
atheromatous carotid samples shows that the healthy tis-
sue has a lower fractal dimension than atheromatous, in
agreement with Asvestas et al. [60], Rakebrandt et al.
[61] and Niu et al. [54], who used statistical and textural
measures based on fractal geometry to quantify texture
features from ultrasound (US) B-mode images of carotid
atherosclerotic plaques.
Furthermore, when G0 dendrimers are deposited onto
healthy tissue, the fractal dimension is increased, whereas
when they are deposited onto atheromatous carotid tis-
sues, the fractal dimension is reduced.
Moreover, when conjugated G0 dendrimers with ZnPc
are deposited onto athermanous carotid tissues, the frac-
tal dimension is reduced further.
Finally, images of the G0 dendrimers on symptomatic or
asymptomatic tissue give higher fractal dimensions than
images of the G0 dendrimers (0.05 M or 0.025 M) depos-
ited onto plain glass, demonstrating that both substrate
type and roughness greatly mediate the agglomerating
behaviour of the drugs.
Minkowski functionals
The Minkowski functionals, i.e. the volume V, Figure 12,
the boundary length S, Figure 13 and the connectivity
(Euler characteristic) x, Figure 14, are shown for the AFM
images of Figures 4, 5, 6 and 7. The Minkowski volume
curves in Figure 12 represent the volume of the rough re-
gions, i.e. the number of pixels with a height threshold lar-
ger than z, and they are decreased monotonously from 1 to
0. For the set of 1 × 1 μm AFM images, Figure 12a, it is
shown that, in contrast to the carotid tissue that can be
either healthy or atheromatous, which both show a nearly
point symmetric behaviour with respect to V = 0.5, Z = 48
nm and Z = 24 nm, respectively, the samples that contained
the deposited PAMAM dendrimers favour the black areas.
For the set of 2 × 2 μm AFM images, Figure 12b, it is
shown that symptomatic and asymptomatic carotid tis-
sues, as well as atheromatous carotid tissue with PAMAM
dendrimers conjugated with ZnPcs, show a nearly point
symmetric behaviour with respect to V = 0.5 and Z = 55
nm, Z = 79 nm and Z = 176 nm, respectively. The carotid
tissues where only G0 dendrimers were deposited are
shown to have an asymmetrical behaviour. More specific-
ally, the healthy tissue with dendrimers favours the black
areas (smooth regions), while the atheromatous one fa-
vours white areas (rough regions). For the set of 3 × 3 μm
AFM images, Figure 12c, it is shown that atheromatous
Figure 7 AFM images (5 × 5 μm) showing (a) a healthy carotid tissue, (b) an atheromatous carotid tissue, (c) an atheromatous carotid tissue with G0
PAMAM dedrimers, (d) an atheromatous carotid tissue with G0 PAMAM dedrimers conjugated with ZnPc and (e) a highly diluted solution (0.025 M) of
dendrimers on glass. (f) The corresponding height distribution of the 5 × 5 μm samples.
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dendrimers conjugated with ZnPcs show a nearly point
symmetric behaviour with respect to V = 0.5 and Z = 100
nm and Z = 278 nm, respectively. The same trend is ob-
served in the curves of Figure 12d for the 5 × 5 μm AFM
images. The curves of the plain (healthy or atheromatous)
or G0/ZnPc-treated tissue show a nearly point symmetric
behaviour with respect to V = 0.5 and Z = 165 nm, Z =
136 nm and Z = 253 nm, respectively, while the samples(tissue or glass) where only dendrimers were deposited
show an asymmetrical behaviour.
The Minkowski boundary length, Figure 13, tends to
zero for nearly flat and most rough areas and reaches its
maximum in the intermediate threshold range. For the set
of 1 × 1 μm AFM images, Figure 13a, it is shown that the
samples containing deposited G0 dendrimers have narrow
and intense Gaussian curves, while the carotid tissue that
is either symptomatic or asymptomatic shows asymmetric
Figure 8 Log-log plots illustrating calculation of fractal dimension by different methods for the 1 × 1 μm AFM images. (a) Variance, (b) cube counting,
(c) triangulation and (d) power spectrum.
Figure 9 Log-log plots illustrating calculation of fractal dimension by different methods for the 2 × 2 μm AFM images. (a) Variance, (b) cube counting,
(c) triangulation and (d) power spectrum.
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Figure 10 Log-log plots illustrating calculation of fractal dimension by different methods for the 3 × 3 μm AFM. (a) Variance, (b) cube counting,
(c) triangulation and (d) power spectrum.
Figure 11 Log-log plots illustrating calculation of fractal dimension by different methods for the 5 × 5 μm AFM images. (a) Variance, (b) cube counting,
(c) triangulation and (d) power spectrum.
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Table 2 Fractal dimensions (Df) calculated by four different methods
Variance Cube counting Triangulation Power spectrum
1 × 1 μm
Healthy 2.23 2.18 2.23 1.68
Atheromatous 2.41 2.25 2.34 1.89
Healthy + PAMAM 2.42 2.13 2.18 2.01
Glass + PAMAM (0.05 M) 2.36 2.21 2.26 2.44
Glass + PAMAM (0.025 M) 2.49 2.19 2.22 2.05
2 × 2 μm
Healthy 2.30 2.14 2.21 1.95
Atheromatous 2.52 2.24 2.29 1.66
Healthy + PAMAM 2.49 2.22 2.28 2.40
Atheromatous + PAMAM 2.44 2.17 2.14 2.43
Atheromatous + PAMAM + ZnPc 2.19 2.13 2.18 1.56
3 × 3 μm
Atheromatous 2.32 2.19 2.25 1.29
Atheromatous + PAMAM + ZnPc 2.30 2.14 2.20 1.50
5 × 5 μm
Healthy 2.28 2.22 2.26 1.47
Atheromatous 2.53 2.23 2.30 1.84
Atheromatous + PAMAM 2.33 2.18 2.24 1.64
Atheromatous + PAMAM + ZnPc 2.33 2.19 2.28 1.47
Glass + PAMAM (0.025 M) 2.34 2.08 2.14 1.73
PAMAM, polyamidoamine; ZnPc, zinc phthalocyanine.
Figure 12 Minkowski volume of (a) 1 × 1 μm, (b) 2 × 2 μm, (c) 3 × 3 μm and (d) 5 × 5 μm AFM images.
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Figure 13 Minkowski boundary of (a) 1 × 1 μm, (b) 2 × 2 μm, (c) 3 × 3 μm and (d) 5 × 5 μm AFM images.
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images, Figure 13b, it is shown that healthy and atheroma-
tous tissue have Gaussian curves, healthy carotid tissue
with G0 dendrimers has a narrow and more intense
Gaussian peak and the deposition of G0 dendrimers onFigure 14 Minkowski connectivity of (a) 1 × 1 μm, (b) 2 × 2 μm, (c) 3 × 3atheromatous carotid tissue results in a very asymmetric
peak. However, the addition of the ZnPc nanodrug tends
to give a nearly symmetrical broad curve with two peaks
(non-Gaussian). For the set of 3 × 3 μm AFM images,
Figure 13c, it is shown again that the deposition of G0μm and (d) 5 × 5 μm AFM images.
Figure 15 AFM images of individual endothelial, THP-1 and SMC cells. (a) Human Brachiocephalic Artery Endothelial Cell (HBcAEC-ECACC™) isolated
from normal brachiocephalic arteries. (b) THP-1 (ATCC®TIB-202™) cell derived from a 1-year-old boy with leukemia. (c) Human Brachiocephalic Artery
SMC cell (HBcASMC ECACC™) isolated from normal brachiocephalic arteries. (d) AFM image of endothelial cell at higher magnification. The statistical
surface parameters of individual cells and healthy arteries differ significantly, Additional file 3, suggesting dissimilar nanodrug uptake efficiency between
tissue and individual cell.
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when compared to the plain atheromatous carotic. The
same trend is also verified in the set of 5 × 5 μm AFM im-
ages, Figure 13d.
The Minkowski connectivity (Euler characteristic x)
describes the topological structure of the pattern. It is
negative (positive) if many disconnected flat (rough)
components dominate the image. A vanishing Euler char-
acteristic indicates a highly connected structure with an
equal amount of flat and rough components [70]. In
Figure 14a (1 × 1 μm), the Minkowski connectivity de-
creases very sharply at τχ = 1.4 (2.0) to the minimum
negative value at τχ = 1.7 (3.1) nm for the images of G0
dendrimers on glass with a concentration of 0.025 M
(0.05 M). Then, the Minkowski connectivity increases
very sharply until the maximum positive value at 2.0 (3.8)
nm and then vanishes at 2.9 (4.3) nm. The Minkowski
connectivity of the image of the healthy carotid tissue
with G0 decreases more smoothly at τχ = 4.3 nm to
the minimum negative value at τχ = 7.3 nm and then
rises until the maximum positive value at 9.6 nm.
After that, it decreases gradually until it vanishes at15 nm. In contrast, the Minkowski connectivity of the
image of the plain healthy carotid tissue shows fluctu-
ations, with the minimum negative value at 21.2 nm
and the maximum positive value at 30.6 nm. This is more
pronounced for the Minkowski connectivity of the ather-
omatous carotid tissue, where several minima and maxima
are demonstrated.
In Figure 14b (2 × 2 μm), the Minkowski connectivity
of the plain atheromatous carotid tissue starts to decrease
early at 7.5 nm to the minimum value at 52.5 nm and
then rises to the maximum value at 86.8 nm, while the
Minkowski connectivity of the plain asymptomatic ca-
rotid tissue displays a plateau of approximately 26 nm
when it reaches the minimum and maximum values at 46
nm and 85 nm, respectively. Furthermore, the addition of
G0 on the healthy tissue results in sharp peaks of the
Minkowski connectivity, with a minimum negative value
at 38.3 nm and maximum positive value at 42.8 nm.
However, the addition of G0 on the atheromatous carotid
tissue results in strong fluctuations of the Minkowski
connectivity from approximately 136 nm to 205 nm
when it starts vanishing. This phenomenon is remarkably
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placed on the atheromatous carotid tissue. In Figure 14c
(3 × 3 μm), the Minkowski connectivity of the plain ather-
omatous carotid tissue has a minimum value at 78.7 nm
and maximum value at 116.1 nm, while the Minkowski
connectivity of the atheromatous carotid tissue with the
added conjugated dendrimers with ZnPc displays a plat-
eau of 45 nm at approximately 223 nm for negative values
and another plateau of 45 nm at approximately 308 nm
for maximum values.
In Figure 14d (5 × 5 μm), the Minkowski connectiv-
ity decreases very sharply at τχ = 16.6 nm to the mini-
mum negative value at τχ = 18.8 nm for the images of
G0 on glass with a concentration of 0.025 M. Then,
the Minkowski connectivity increases very sharply until
the maximum positive value at 19.4 nm and then van-
ishes approximately at 26 nm. Atheromatous carotid tis-
sue with G0 and atheromatous carotid tissue with G0
conjugated with ZnPc show almost the same behaviour
regarding the Minkowski connectivity, but the latter has
fewer fluctuations. Concerning the plain asymptomatic ca-
rotid tissue, the Minkowski connectivity displays a broad
plateau with several local minima for negative values at
approximately 120 nm and two local maxima at 184 nm
and 247 nm. In contrast, the Minkowski connectivity of
the asymptomatic carotid tissue has a minimum value at
90 nm and then fluctuates around zero until it reaches a
positive plateau from 155 nm to 195 nm. Finally, it grad-
ually decreases to a zero value.
Discussion
Normal vascular physiology results in tight (<2 nm) endo-
thelial junctions, which will restrict nanoparticle distribu-
tion, whereas a dysfunctional endothelium leads to large
gaps that allow NPs to penetrate the endothelial barrier,
deposit at local sites and remain retained locally, owing to
impaired lymphatic drainage [72]. This phenomenon,
which occurs in pathological conditions such as cancer or
atherosclerosis, is known as the enhanced permeation and
retention effect (EPR) [12]. Nanoparticle size is one crucial
determinant of accumulation and penetration into dis-
eased tissue, and NPs with sub-100 nm sizes are optimal
for the EPR [73]. Therefore, the adsorption and aggrega-
tion of G0 is a major parameter of nanodrug efficacy.
The adsorption and aggregation of dendrimers to mica
and silica surfaces, particularly of higher generations, was
studied by AFM in several works [74-78]. These studies
revealed that such dendrimers flatten substantially upon
adsorption and that sometimes aggregates can be ob-
served on the surface, particularly at a higher pH. It was
further reported that the PAMAM dendrimers adsorb on
mica and silica in correlated liquid-like monolayers and
that repulsive electrostatic interactions between the den-
drimers lead to low adsorption densities.Mecke et al. [74] showed experimentally using AFM
and via atomistic molecular dynamics simulations that
both charged and uncharged PAMAM dendrimers
strongly adsorb to mica surfaces, resulting in deform-
ation of the molecules. The heights of the molecules, as
determined by AFM, were much less than the diameter
in their spherically symmetric state and did not depend
strongly on the charge of the branch ends. Flattening of
the dendrimers also occurred at the liquid-solid interface,
although to a lesser degree. Furthermore, they found that
the PAMAM dendrimers in aqueous environments in-
crease in height and volume due to swelling. Studies
combining optical reflectometry and AFM demonstrated
that the adsorption process of PAMAM dendrimers to
silica substrates is driven by attractive forces between the
dendrimers and the substrate [75]. Thus, the initial ad-
sorption rate depended on the solution composition only
weakly. However, the maximum adsorbed amount in-
creased strongly with the ionic strength and pH.
In another AFM study of PAMAM dendrimers [76], it
was noted that the drying procedure could induce the for-
mation of aggregates by capillary forces and, therefore, in-
fluence the relative positions of the deposited dendrimers.
Thus, under different conditions, the drying process could
indeed result in a rearrangement within the adsorbed
dendrimer layer. However, the authors noted that the
amount of deposited dendrimers remained constant inde-
pendent of the relative positions. Recently, Yu et al. [77]
showed that aggregates’ morphology of the amphiphilic
G1 PAMAM dendrimer onto the mica substrate was
seemingly spherical at low concentration and that semi-
continuous films or network structure films were formed
at high concentrations. Finally, Müller et al. [78] stated
that the dendrimer shapes depend on the substrate type
and that the aqueous solvent may influence dendrimer
conformation, as they observed the formation of large ag-
gregates on a HOPG surface when water was used as a
solvent using AFM.
Studies of PAMAM distribution on biological samples
are rather scarce [79-82]. For example, Dobrovolskaia
et al. [79] reported in in vitro studies the effects of the
size and surface terminal groups of PAMAM dendrimers
on healthy human platelets. The study revealed that only
dendrimers of higher generations with positive charge,
not negative or neutral or small cationic dendrimers,
contributed to the aggregation of human platelets in vitro.
It was stated that large cationic PAMAM dendrimers in-
duce platelet aggregation through the disruption of mem-
brane integrity. In another recent study of G4 PAMAM
dendrimer-treated rat brains [80], AFM images showed
evidence of dendrimers in the inner capillary wall and
demonstrated that PAMAM dendrimers are present at
the blood-brain barrier (BBB). Furthermore, it was found
that, while the height of distinct NPs ranged only from 2.7
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expected diameter of the G4 PAMAM dendrimers, indi-
cating that the measured NPs could be aggregates of den-
drimers. Furthermore, Kitchens et al. [81] found that the
extravasation time of PAMAM-NH2 dendrimers (G1-G4)
across the microvascular endothelium of the cremaster
muscle of male golden Syrian hamsters (Mesocricetusaur-
atus) is size dependent due to increased exclusion from
the endothelial pores. Finally, Markowicz-Piasecka et al.
[82], in the only study to the authors’ knowledge on the
effect of PAMAM dendrimers on the endothelium of
human arteries, found that the influence of PAMAM den-
drimers on the process of clot formation and fibrinolysis
depends on the concentration and generation of the
dendrimer and that G3 and G4 PAMAM dendrimers
adversely affected human endothelium.
Here, the AFM study of G0 and G0/ZnPc conjugates,
followed by textural analysis in terms of the root mean
square surface roughness (Rq), the surface roughness
(Ra), the mean Zð Þ; media (Z1/2), mode (Zmp) and range
(Rt) heights, the maximum valley depth (Rmvd), the max-
imum peak height (Rmph), skewness (Rsk), kurtosis (Rku),
fractal dimension and Minkowski functionals, shows in-
teresting results. First, the adsorption and aggregation
of G0 on human tissue differs greatly from those on a
flat inorganic material. Indeed, from the AFM images
and the corresponding statistical analysis, it is shown
that G0 are more or less monodisperse on the latter,
while they spread more uniformly on the human tissue.
Furthermore, differences on the local morphological
characteristics of plain symptomatic and asymptomatic
tissues were found. These differences, in correlation
with the EPR effect, lead to selective aggregation of the
dendrimers to the atheromatous carotid tissues. This is
evident from the opposite signs of the relative differ-
ence of the fractal dimensions as well as from the be-
haviour of the Minkowski functional curves.
The conjugation of ZnPcs to G0 provides significant
changes of surface roughness parameters compared to
the dendrimers alone and the skewness and kurtosis pa-
rameters show significant distortions of PDF’s and aggre-
gation features under G0/ZnPc loading. It seems that the
addition of the hydrophobic ZnPcs counterbalances the
effects of PAMAM dendrimers on the atheromatous ca-
rotid tissue, suggesting that both the surface type and the
drug composition mediate the drug delivery efficiency, in
full agreement with previous nanothermodynamic studies
of nanoparticles on surfaces [28,83].
Indeed, it is known that phospholipids of the cellular
membrane extend their hydrophilic head to the outer cell
environment [12] and that the environment around a cell
membrane is hydrophilic. The cell membrane is being
spanned by transmembrane proteins; these proteins usu-
ally have their N-terminal domain extracellular, and theC-terminal domain is found in the inner cell. Thus, the
application of the hydrophobic environment around a cell
membrane could change the hydrophilic interactions
between transmembrane proteins and the extracellular
matrix (ECM), which leads to a partial disorder of balance
in the cell and its outer environment due to different
thermodynamic environments and polar-entropic compe-
tition at the nanoscale [83]. Nanoparticle encapsulation
and change of local thermodynamic environment enhance
image contrast in computer tomography of atheromatous
plaque [84]. Finally, large morphological differences be-
tween tissue and individual endothelial, SMC and THP1
cells, Figure 15 and Additional file 3: Table S3.1, imply
different nanodrug uptake efficiency by individual cells
and further studies are needed towards this direction.
Conclusions
In conclusion, the results of this work show that the
addition of G0 PAMAM dendrimers or G0 PAMAM/
ZnPc conjugates to the carotid tissue, either healthy or
atheromatous, significantly alters the local texture char-
acteristics of human carotids at the nanoscale, indicating
different agglomerating responses of the G0 NPs. Most
importantly, all statistical quantities showed that the de-
position of nanodrug carriers on the healthy tissue seems
to have an inverse impact in comparison to the depos-
ition on atheromatous tissue, clearly suggesting the small
size agglomeration of G0 NPs on the healthy tissue, with
a particle size less than the surface roughness parameters
of the tissue. In addition, different size agglomeration be-
tween G0 and G0/ZnPc and selective aggregation of the
dendrimers to the atheromatous carotid tissues is ob-
served. However, in addition to the size and composition
of G0 aggregates, the penetration of dendrimers across
the endothelial barrier depends on other important fea-
tures, such as concentration, incubation time, efflux
transport, surface charge, modification [85], local ther-
modynamic conditions [28] and polar-entropic competi-
tion [83]; therefore, future studies comprising all these
parameters are necessary.
Additional files
Additional file 1: Surface roughness parameters of healthy and
atheromatous human tissues loaded with G0 and G0/ZnPc
conjugated nanodrugs. The root mean square surface roughness (Rq),
the surface roughness (Ra), the mean Zð Þ; media (Z1/2), mode (Zmp) and
range (Rt) heights, the maximum valley depth (Rmvd), the maximum peak
height (Rmph), skewness (Rsk) and kurtosis (Rku) of healthy and
atheromatous human tissues loaded with G0 PAMAM and G0/ZnPc
conjugated nanodrugs are tabulated. Statistical analysis suggests that
both the surface type and the drug composition mediate the drug
delivery efficiency.
Additional file 2: AFM images, line analysis and size distribution of
ZnPc nanoparticles on Au and Si surfaces. Size statistics of aggregation
of ZnPc nanoparticles on gold (Au) and Si standard test surfaces is different
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to aggregate at average sizes much higher than the surface roughness
parameters of the test surfaces. This response is owing to the presence of
electron charges on the surface of ZnPc nanoparticles and demonstrated by
conductive atomic force microscopy. In case of conjugation of ZnPc with
the G0 dendrimers, the negative charges are compensated to give nearly
neutral nanoparticles of smaller size.
Additional file 3: Surface roughness parameters of individual
endothelial, THP-1 cells and SMC and preparation of cell cultures.
Table S3.1. Surface roughness parameters of individual endothelial, THP-
1 cells and SMC. Surface roughness parameters of THP-1 (ATCC®TIB-202™),
HBcAEC (ECACC) and HBcASMC (ECACC) cell lines. They are different from
the atheromatous surface roughness parameters, indicating dissimilar
nanodrug uptaking efficiency. Table S3.2. Preparation of cell cultures.
THP-1 (ATCC®TIB-202™), HBcAEC (ECACC) and HBcASMC (ECACC) cell lines
were used. All cell cultures were performed in an incubator at a 95% w/w
ambient air, 5% w/w CO2 gaseous environment and the temperature is
maintained at 37°C.
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